Zurcher Kantonalbank Zurich Cantonalbank Has $83,000 Stock Holdings in 23andMe Holding Co. (NASDAQ:ME)

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in 23andMe Holding Co. (NASDAQ:MEGet Rating) by 14.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,295 shares of the company’s stock after selling 6,375 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in 23andMe were worth $83,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Strs Ohio boosted its stake in 23andMe by 17.3% in the fourth quarter. Strs Ohio now owns 95,100 shares of the company’s stock valued at $205,000 after buying an additional 14,000 shares in the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of 23andMe in the 4th quarter valued at $26,000. Allworth Financial LP boosted its position in shares of 23andMe by 1,332.7% during the 4th quarter. Allworth Financial LP now owns 28,654 shares of the company’s stock worth $2,026,000 after purchasing an additional 26,654 shares in the last quarter. MQS Management LLC acquired a new stake in 23andMe in the 3rd quarter valued at $41,000. Finally, Bank of New York Mellon Corp increased its holdings in 23andMe by 70.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 809,336 shares of the company’s stock worth $2,315,000 after purchasing an additional 333,241 shares in the last quarter. Institutional investors and hedge funds own 29.49% of the company’s stock.

23andMe Stock Performance

23andMe stock opened at $2.11 on Thursday. The stock has a market cap of $964.80 million, a PE ratio of -2.97 and a beta of 1.37. The firm’s 50-day simple moving average is $2.18 and its 200 day simple moving average is $2.51. 23andMe Holding Co. has a fifty-two week low of $1.74 and a fifty-two week high of $6.31.

23andMe (NASDAQ:MEGet Rating) last released its quarterly earnings results on Wednesday, February 8th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). 23andMe had a negative net margin of 103.07% and a negative return on equity of 36.26%. The firm had revenue of $67.00 million for the quarter, compared to analysts’ expectations of $65.90 million. During the same quarter last year, the firm earned ($0.21) earnings per share. The firm’s revenue for the quarter was up 17.8% on a year-over-year basis.

23andMe Profile

(Get Rating)

23andMe Holding Co operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.

Recommended Stories

Institutional Ownership by Quarter for 23andMe (NASDAQ:ME)

Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.